Salta al contenuto
VuFind
English
Deutsch
Español
Français
Italiano
日本語
Nederlands
Português
Português (Brasil)
中文(简体)
中文(繁體)
Türkçe
עברית
Gaeilge
Cymraeg
Ελληνικά
Català
Euskara
Русский
Čeština
Suomi
Svenska
polski
Dansk
slovenščina
اللغة العربية
বাংলা
Galego
Tiếng Việt
Hrvatski
हिंदी
Հայերէն
Українська
Sámegiella
Монгол
Lingua
Tutti i Campi
Titolo
Autore
Soggetto
Collocazione
ISBN/ISSN
Tag
Cerca
Avanzata
Discordance between power Dopp...
Citazione
Invia SMS
Invia email
Stampa
Esporta il record
Esporta a RefWorks
Esporta a EndNoteWeb
Esporta a EndNote
PLink permanente
Discordance between power Doppler and DAS28 assessment of remission induction in a randomised, placebo-controlled stud of infliximab therapy in early rheumatoid arthritis
Dettagli Bibliografici
Autori principali:
Taylor, P
,
Steuer, A
,
McClinton, C
,
Blomley, M
,
Wagner, C
,
Marsters, P
,
Maini, R
Natura:
Conference item
Pubblicazione:
2005
Posseduto
Descrizione
Documenti analoghi
MARC21
Documenti analoghi
Comparison of ultrasonographic assessment of synovitis and joint vascularity with radiographic evaluation in a randomized, placebo-controlled study of infliximab therapy in early rheumatoid arthritis.
di: Taylor, P, et al.
Pubblicazione: (2004)
Comparison of ultrasonographic assessment of synovitis and joint vascularity with radiological evaluation in a randomized, placebo-controlled study of infliximab therapy in early rheumatoid arthritis.
di: Taylor, P, et al.
Pubblicazione: (2003)
Comparison of remission induction in erosive early KA assessed by DAS28 calculated using either ESR or CRP in infliximab plus MTX combination therapy or MTX monotherapy
di: Taylor, P, et al.
Pubblicazione: (2005)
Kinetics of change in erosion scores as assessed by plain radiography and high frequency ultrasound in a randomised, controlled trial of infliximab plus MTX versus MTX only therapy in erosive early rheumatoid arthritis
di: Taylor, P, et al.
Pubblicazione: (2005)
Comparison of ultrasonographic measures of synovitis and radiographic assessment of structural damage over two years in a randomised, controlled trial of infliximab therapy in erosive early rheumatoid arthritis.
di: Taylor, P, et al.
Pubblicazione: (2004)